The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index; 55 of the 94 sources its claims cite were checked for support.
Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A
Open accessAbstract
The protein phosphatase 2A (PP2A) heterotrimer PP2A-B56α is a human tumour suppressor. However, the molecular mechanisms inhibiting PP2A-B56α in cancer are poorly understood. Here, we report molecular level details and structural mechanisms of PP2A-B56α inhibition by an oncoprotein CIP2A. Upon direct binding to PP2A-B56α trimer, CIP2A displaces the PP2A-A subunit and thereby hijacks both the B56α, and the catalytic PP2Ac subunit to form a CIP2A-B56α-PP2Ac pseudotrimer. Further, CIP2A competes with B56α substrate binding by blocking the LxxIxE-motif substrate binding pocket on B56α. Relevant to oncogenic activity of CIP2A across human cancers, the N-terminal head domain-mediated interaction with B56α stabilizes CIP2A protein. Functionally, CRISPR/Cas9-mediated single amino acid mutagenesis of the head domain blunted MYC expression and MEK phosphorylation, and abrogated triple-negative breast cancer in vivo tumour growth. Collectively, we discover a unique multi-step hijack and mute protein complex regulation mechanism resulting in tumour suppressor PP2A-B56α inhibition. Further, the results unfold a structural determinant for the oncogenic activity of CIP2A, potentially facilitating therapeutic modulation of CIP2A in cancer and other diseases.
Overview
CoChat Summary
TL;DR
CIP2A inhibits the tumour suppressor PP2A-B56α by binding the B56α N-terminal head domain, displacing PP2A-A to form a CIP2A-B56α-PP2Ac pseudotrimer, and sterically blocking B56α LxxIxE-motif substrate binding. A single K21A mutation in the CIP2A head domain destabilizes CIP2A, disrupts CIP2A-B56α interaction, and abrogates triple-negative breast cancer growth in vitro and in vivo.
Key findings
- CIP2A binds B56α primarily through its N-terminal head domain, displaces the PP2A-A subunit from the PP2A-B56α trimer, and forms a CIP2A-B56α-PP2Ac pseudotrimer; it also blocks the B56α LxxIxE-motif substrate pocket, out-competing BubR1 from B56α.
- Head-domain mutations affect full-length CIP2A protein levels: K8A “practically abolished” expression, K21A and K40A significantly inhibited it, and A24E increased it; K647A rescued K8A expression, linking stability to C-terminal ubiquitination.
- CRISPR/Cas9 K21A mutant MDA-MB-231 clones showed almost complete loss of CIP2A-B56α interaction by PLA, were “almost completely incompetent” to grow on soft agar, and in orthotopic xenografts clone 1 produced only 5/8 palpable tumours with mean volume 113 mm³ after 30 days.
- AP-MS showed CIP2A overexpression decreased B56α association with PPP2R1A and, among significantly affected B56α interactors, 80% had decreased B56α binding and 63% had a candidate LxxIxE motif; phosphoproteomics found 78 phosphopeptides from 63 proteins downregulated in K21A cells, with 53% containing a candidate LxxIxE motif and an additional 15% being interactors of such proteins (68% total).
Methods
- Multidisciplinary structural and biochemical approach: chemical cross-linking coupled to mass spectrometry (XL-MS) with DSS and DMTMM, GST pull-down assays, size-exclusion chromatography, and in vitro competition assays using recombinant CIP2A fragments, B56α, PP2Ac, and BubR1(647-720).
- Cell-based validation used 22RV1 prostate cancer cells, MDA-MB-231 triple-negative breast cancer cells, HEK-293-T cells, and murine NIH3T3 cells; CRISPR/Cas9 with two gRNAs generated MDA-MB-231 CIP2A K21A single-cell clones, compared with RNP-transfected controls.
- Proteomic analyses included affinity purification coupled to MS (AP-MS) of B56α interactome in NIH3T3 cells and TMT-based phosphoproteomics of MDA-MB-231 control versus CIP2A K21A clone 1; in vivo tumour growth used orthotopic mammary fat pad xenografts in athymic nude mice (control n=7, K21A clone1 n=8, K21A clone2 n=8).
Limitations
- The paper states that XL-MS should be considered a screening experiment whose results need further experimental validation, and that the XL-MS data may contain cross-links that are not functionally relevant.
- The paper states that crystallization of the CIP2A-B56α complex has not been successful and that additional structural studies would be required to understand molecular-level details of CIP2A and NOCIVA interactions with PP2A-B56; it also notes that recombinant full-length CIP2A production remains elusive, so full-length studies relied on V5-tagged constructs in cells.
- The paper states that the data do not exclude other potential mechanisms by which CIP2A promotes oncogenesis; evident from the text, some biochemical experiments had low replication (e.g., size-exclusion chromatography in Fig. 4E, F is labelled N=1), and several head-domain mutants could not be expressed as bacterial proteins due to instability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
37 Valid · 1 Not valid · 7 Not checked · 140 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“CIP2A also broadly regulates cancer cell therapy responses, and its over-expression clinically correlates with relapse from kinase inhibitor therapies27–30.”
§ Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A > Introduction
What the sources say
- Partly supportedcites [27] Kauko, O. et al. Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1. J. Biol. Chem. 295, 4194–4211 (2020). sourceExperimental — accuracy not yet measured
In the ‘Systemic analysis of CIP2A, SET and PME-1 phosphoproteomes’ section (page unavailable), the paper reports that CIP2A positivity in chronic myeloid cells strongly predicts resistance to first-generation tyrosine kinase inhibitors. It does not report relapse after kinase-inhibitor therapy, and its clinical statement is narrower than the claim’s reference to kinase-inhibitor therapies generally. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [28] Kauko O. et al. PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Sci. Transl. Med. 10, eaaq1093 (2018). source
- Not checked — no full text of the sourcecites [29] Lucas, C. M. et al. Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. Leukemia 29, 1514–1523 (2015). source
- Not checked — no full text of the sourcecites [30] Choi Y. A. et al. Increase in CIP2A expression is associated with doxorubicin resistance. FEBS Lett. 585, 755–60 (2011). source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Among the PP2A complexes, PP2A trimers with B56 subunits are predominantly human tumour suppressors4–7.”
§ Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A > Introduction
What the sources say
- Not checked — no full text of the sourcecites [4] Lambrecht, C. et al. Loss of protein phosphatase 2A regulatory subunit B56delta promotes spontaneous tumorigenesis in vivo. Oncogene 37, 544–552 (2018). source
- Not checked — no full text of the sourcecites [5] Mao, Z., Liu, C., Lin, X., Sun, B. & Su, C. PPP2R5A: a multirole protein phosphatase subunit in regulating cancer development. Cancer Lett. 414, 222–229 (2018). source
- Partly supportedcites [6] Sablina, A. A., Hector, M., Colpaert, N. & Hahn, W. C. Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res. 70, 10474–10484 (2010). sourceExperimental — accuracy not yet measured
The Results section (page unavailable) reports that suppressing B56α or B56γ promoted anchorage-independent growth in human cells, supporting a tumour-suppressive role for complexes containing those subunits. It does not establish that PP2A trimers with B56 subunits are predominantly tumour suppressors across human tumours. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [7] Chen, W. et al. Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 5, 127–136 (2004). source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, fully consistent with the requirement of PP2A-B56 inhibition for anchorage-independent growth6,7, CIP2A K21A targeted clones were almost completely incompetent to grow as spheres on soft agar (Fig. 3F, G).”
§ Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A > Results > Single amino acid mutation on the N-terminal head domain of CIP2A abrogates TNBC tumorigenicity
What the sources say
- Partly supportedcites [6] Sablina, A. A., Hector, M., Colpaert, N. & Hahn, W. C. Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res. 70, 10474–10484 (2010). sourceExperimental — accuracy not yet measured
The Results (page unavailable) report that suppressing PP2A B56α or B56γ permitted HEK TER cells to grow anchorage-independently, supporting a role for B56 inhibition in that growth. They do not establish that B56 inhibition is required, and this paper does not report the CIP2A K21A clone result, which the citing sentence attributes to its own Fig. 3F–G. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [7] Chen, W. et al. Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 5, 127–136 (2004). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“an additional 15% of proteins identified in our screen are interactors of proteins with validated or predicted LxxIxE docking motifs46,48 (Fig. 6D and Supplementary Data 4).”
§ Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A > Results > Validation of the “hijack and mute” model of PP2A-B56α inhibition by CIP2A in cellulo
What the sources say
- Not checked — no full text of the sourcecites [46] Kruse, T. et al. The Ebola virus nucleoprotein recruits the host PP2A-B56 phosphatase to activate transcriptional support activity of VP30. Mol. Cell 69, 136–145 e136 (2018). source
- Supportedcites [48] Smith, R. J. et al. PP1 and PP2A use opposite phospho-dependencies to control distinct processes at the kinetochore. Cell Rep. 28, 2206–2219 e2208 (2019). source
The Results section (page unavailable) says the paper curated validated and predicted LxxIxE motifs in proteins, and STAR Methods describes the validated and predicted motif sets. The citation supports identifying motif-bearing proteins; the 15% figure concerns the citing authors’ own screen, not a result attributed to this source. (LLM, conf=0.89)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“therapeutic impact of inhibition of CIP2A protein expression has been validated by numerous studies across human cancer types18,20,21,23,33,34.”
§ Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A > Discussion
What the sources say
- Not checked — no full text of the sourcecites [18] Laine, A. et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov. 3, 182–197 (2013). source
- Not checked — no full text of the sourcecites [20] Lucas, C. M. et al. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 117, 6660–6668 (2011). source
- Partly supportedcites [21] Junttila, M. R. et al. CIP2A inhibits PP2A in human malignancies. Cell 130, 51–62 (2007). sourceExperimental — accuracy not yet measured
The Results report that siRNA depletion of CIP2A reduced tumor growth in mice injected with HeLa or head-and-neck cancer cells. The Discussion describes CIP2A inhibition as a potential future cancer therapy. This single preclinical study does not establish a validated therapeutic impact across human cancer types or itself constitute the numerous studies claimed. (LLM, conf=0.88)
- Partly supportedcites [23] Elgendy, M. et al. Combination of hypoglycemia and metformin impairs tumor metabolic plasticity and growth by modulating the PP2A-GSK3beta-MCL-1 axis. Cancer Cell 35, 798–815 e795 (2019). sourceExperimental — accuracy not yet measured
The Results (p. 10) show that CIP2A depletion, combined with low glucose, induced tumor-cell death; the in vivo Results (p. 13) link lower CIP2A levels to the tumor-restraining effect of metformin during fasting. The Discussion (p. 15) says CIP2A is overexpressed in numerous tumor types, but this paper does not establish that numerous studies have validated the therapeutic impact of inhibiting CIP2A expression across human cancer types. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [33] Soofiyani, S. R., Hejazi, M. S. & Baradaran, B. The role of CIP2A in cancer: a review and update. Biomed. Pharmacother. 96, 626–633 (2017). source
- Partly supportedcites [34] Come, C. et al. CIP2A is associated with human breast cancer aggressivity. Clin. Cancer Res. 15, 5092–5100 (2009). sourceExperimental — accuracy not yet measured
The Translational Relevance section (p. 2) reports that CIP2A depletion reduced breast cancer cell proliferation and inhibited xenograft growth. That supports a potential therapeutic effect in breast cancer models, but the paper calls for further investigation rather than claiming that therapeutic impact has been validated across human cancer types. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
117 more claims · 18 with their cited sources checked
Create a free account to see all 185 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 43
- It may state two separate claims as one. 25
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A > Results > CIP2A mutes LxxIxE motif-dependent substrate binding to B56α
“Triple B56α mutant (K181A/K217A/K227A) exhibits loss of K227 (B56)-D117(PP2A-A) salt bridge.”
§ Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A > Results > CIP2A mutes LxxIxE motif-dependent substrate binding to B56α
“This is best explained by polar interactions between D177 of the PP2A-A subunit and K227 of the B56α (Fig. 5I; PDBID 6NTS).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A > Results > CIP2A hijacks B56α and PP2Ac from the PP2A-B56α heterotrimer
“E, F Size-exclusion chromatography analysis of protein complexes between GST (F) or GST-CIP2A(1-560) (G)”
§ Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A > Results > CIP2A hijacks B56α and PP2Ac from the PP2A-B56α heterotrimer
“in the control samples co-incubated with GST (Fig. 4E, middle panel), the A-B56α-PP2Ac trimer components co-eluted in fractions 3 and 4, and without GST, whereas in the samples incubated with GST-CIP2A(1-560) (Fig. 4F, middle panel), CIP2A co-eluted with B56α and PP2Ac”
Citations
Cites
Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D. J., Inuganti, A., Griss, J., Mayer, G., Eisenacher, M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1106 · Cited by 6,693
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677
Self-citationFrom Promiscuity to Precision: Protein Phosphatases Get a Makeover
Virshup, D. M., & Shenolikar, S. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.02.015 · Cited by 641
Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme
Cho, U. S., & Xu, W. (2007) · Nature · doi:10.1038/nature05351 · Cited by 459 · cited 5×
“The data show that the CIP2A(1-560) residues cross-linked to B56α are located primarily in the N-terminal head domain (K18, K21, E23, E34, K40) with an additional residue at the C-terminus (K490) (Fig.”
BackgroundMethodInfluentialSelf-citationStructure of the Protein Phosphatase 2A Holoenzyme
Xu, Y., Xing, Y., Chen, Y., Chao, Y., Lin, Z., Fan, E., Yu, J. W., Strack, S., Jeffrey, P. D., & Shi, Y. (2006) · Cell · doi:10.1016/j.cell.2006.11.033 · Cited by 450 · cited 5×
“The data show that the CIP2A(1-560) residues cross-linked to B56α are located primarily in the N-terminal head domain (K18, K21, E23, E34, K40) with an additional residue at the C-terminus (K490) (Fig.”
BackgroundMethodInfluentialKinomeXplorer: an integrated platform for kinome biology studies
Horn, H., Schoof, E. M., Kim, J., Robin, X., Miller, M. L., Diella, F., Palma, A., Cesareni, G., Jensen, L. J., & Linding, R. (2014) · Nature Methods · doi:10.1038/nmeth.2968 · Cited by 338 · cited 5×
“The data show that the CIP2A(1-560) residues cross-linked to B56α are located primarily in the N-terminal head domain (K18, K21, E23, E34, K40) with an additional residue at the C-terminus (K490) (Fig.”
BackgroundMethodInfluentialEriksson, J. E., He, T., Trejo-Skalli, A. V., Härmälä-Braskén, A.-S., Hellman, J., Chou, Y.-H., & Goldman, R. D. (2004) · Journal of Cell Science · doi:10.1242/jcs.00906 · Cited by 336 · cited 5×
“The data show that the CIP2A(1-560) residues cross-linked to B56α are located primarily in the N-terminal head domain (K18, K21, E23, E34, K40) with an additional residue at the C-terminus (K490) (Fig.”
BackgroundMethodInfluentialIdentification of specific PP2A complexes involved in human cell transformation
Chen, W., Possemato, R., Campbell, K. T., Plattner, C. A., Pallas, D. C., & Hahn, W. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00026-1 · Cited by 325 · cited 5×
“The data show that the CIP2A(1-560) residues cross-linked to B56α are located primarily in the N-terminal head domain (K18, K21, E23, E34, K40) with an additional residue at the C-terminus (K490) (Fig.”
BackgroundMethodInfluentialNguyen, D. N., Roth, T. L., Li, P. J., Chen, P. A., Apathy, R., Mamedov, M. R., Vo, L. T., Tobin, V. R., Goodman, D., Shifrut, E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0325-6 · Cited by 312 · cited 5×
“The data show that the CIP2A(1-560) residues cross-linked to B56α are located primarily in the N-terminal head domain (K18, K21, E23, E34, K40) with an additional residue at the C-terminus (K490) (Fig.”
BackgroundMethodInfluentialThe CD28 and CTLA-4 Receptors Associate with the Serine/Threonine Phosphatase PP2A
Chuang, E., Fisher, T. S., Morgan, R. W., Robbins, M. D., Duerr, J. M., Vander Heiden, M. G., Gardner, J. P., Hambor, J. E., Neveu, M. J., & Thompson, C. B. (2000) · Immunity · doi:10.1016/s1074-7613(00)00031-5 · Cited by 303 · cited 5×
“The data show that the CIP2A(1-560) residues cross-linked to B56α are located primarily in the N-terminal head domain (K18, K21, E23, E34, K40) with an additional residue at the C-terminus (K490) (Fig.”
BackgroundMethodInfluential
Cited by
CIP2A induces PKM2 tetramer formation and oxidative phosphorylation in non-small cell lung cancer
Liang, L.-J., Yang, F., Wang, D., Zhang, Y., Yu, H., Wang, Z., Sun, B., Liu, Y., Wang, G., & Zhou, G. (2024) · Cell Discovery · doi:10.1038/s41421-023-00633-0 · Cited by 52
Self-citationRegulation and role of the PP2A-B56 holoenzyme family in cancer
Peris, I., Romero-Murillo, S., Vicente, C., Narla, G., & Odero, M. D. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188953 · Cited by 30
“CIP2A (Cancerous Inhibitor of PP2A) directly binds to PP2A-B56 α , displacing the PP2A A-subunit and thereby hijacking both the B56 α and the catalytic PP2A C-subunit to form a CIP2A-B56 α -PP2Ac pseudo-trimer, muting the B56 α substrate recognition site [41,42].”
CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response
Nagelli, S. G., & Westermarck, J. K. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.09.001 · Cited by 22
Self-citationNeale, D. B., Morris, J. C., Verrills, N. M., & Ammit, A. J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108834 · Cited by 27
Cazzoli, R., Romeo, F., Pallavicini, I., Peri, S., Romanenghi, M., Pérez-Valencia, J. A., Hagag, E., Ferrucci, F., Elgendy, M., Vittorio, O., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112616 · Cited by 18
Self-citation
Metadata
- Authors
- Pavic, K., Gupta, N., Omella, J. D., Derua, R., Aakula, A., Huhtaniemi, R., Määttä, J. A., Höfflin, N., Okkeri, J., Wang, Z., Kauko, O., Varjus, R., Honkanen, H., Abankwa, D., Köhn, M., Hytönen, V. P., Xu, W., Nilsson, J., Page, R., Janssens, V., Leitner, A., & Westermarck, J.
- Affiliations
- Åbo Akademi University (FI)
- KU Leuven (BE)
- Tampere University (FI)
- University of Freiburg (DE)
- ShanghaiTech University (CN)
- University of Luxembourg (LU)
- University of Copenhagen (DK)
- University of Arizona (US)
- ETH Zurich (CH)
- Corresponding author
- Westermarck, Jukka
- ORCID
- Venue
- Nature Communications
- Published
- 2023-02-28
- Volume
- 14
- Issue
- 1
- Pages
- 1143-1143
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC9974998
- OpenAlex
- W4322588601
- Semantic Scholar
- 27959b1ea767636fbd08045c9ade7501faa4e6a7
- Cited by
- 36
- References
- 65
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 11 · 2023: 8
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, cc-by)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Åbo Akademi University Research Portal (submittedVersion, cc-by)
- Tampere University Institutional Repository (Tampere University) (submittedVersion, cc-by)
- Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
- ETH Zürich Research Collection
- Funders
- Suomen Kulttuurirahasto
- K. Albin Johanssons Stiftelse
- Jane ja Aatos Erkon Säätiö
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM144483)
- Academy of Finland (331237)
- Sigrid Juséliuksen Säätiö
- Finnish Cancer Foundations
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- CIP2A, protein phosphatase 2A, oncogenicity, substrate binding pocket, protein stability, MYC expression, MEK phosphorylation, triple-negative breast cancer, protein complex structure
- MeSH terms
- Amino Acids, Autoantigens, Humans, Membrane Proteins, Phosphorylation, Protein Processing, Post-Translational, Catalytic Domain, Intracellular Signaling Peptides and Proteins, Protein Phosphatase 2, Carcinogenesis, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A. https://app.cochat.ai/papers/10.1038/s41467-023-36693-9
- The paper
- Pavic, K., Gupta, N., Omella, J. D., Derua, R., Aakula, A., Huhtaniemi, R., Määttä, J. A., Höfflin, N., Okkeri, J., Wang, Z., Kauko, O., Varjus, R., Honkanen, H., Abankwa, D., Köhn, M., Hytönen, V. P., Xu, W., Nilsson, J., Page, R., . . . Westermarck, J. (2023). Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A. Nature Communications. https://doi.org/10.1038/s41467-023-36693-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.